Прогностическое значение некоторых нейромаркеров при первом эпизоде параноидной шизофрении до назначения терапии

Полный текст:   Только для подписчиков

Рекомендуемое оформление библиографической ссылки:

Сахаров А.В., Мындускин И.В., Голыгина С.Е. Прогностическое значение некоторых нейромаркеров при первом эпизоде параноидной шизофрении до назначения терапии // Российский психиатрический журнал. 2023. №2. С. 38-45.

Аннотация

В одномоментном проспективном исследовании с целью изучения содержания некоторых нейромаркеров в плазме крови у пациентов с первым эпизодом параноидной шизофрении до назначения терапии обследовано 40 пациентов с диагнозом «шизофрения параноидная, период наблюдения менее года» (F20.09). Группу контроля составили 20 здоровых добровольцев. Определение содержания VILIP-1, CCL2 (MCP-1), sTREM-1, sTREM-2, BDNF, TGF-β1, VEGF, β-NGF, sRAGE, IL-6, IL-18, TNF-α, CX3CL1 в сыворотке крови проводили методом проточной флюориметрии. Установлено значимое повышение в крови больных относительно контрольных значений уровня sTREM-1 в 2,2 раза, IL-6 и sRAGE – в 1,8 раза, VILIP-1 и CCL2 – в 1,6 раза. Содержание BDNF оказалось снижено в 1,25 раза. Результаты подтверждают весомую роль нейроиммунных механизмов в развитии шизофрении. Проведенный с помощью нейронной сети анализ установил прогностическую ценность VILIP-1, CCL2 и sRAGE для определения риска развития психоза у больных шизофренией.

Ключевые слова шизофрения; первый эпизод; нейромаркеры; цитокины; хемокины; нейровоспаление; нейронная сеть; прогностическая модель

Литература

1. Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–71. DOI: https://doi.org/10.1016/j.biopsych.2011.04.013 2. Müller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Front Neurosci. 2015;9:372. DOI: https://doi.org/10.3389/fnins.2015.00372 3. Klyushnik TP, Smulevich AB, Zozulya SA, Voronova EI. [Neurobiology of schizophrenia and clinical and psychopathological correlates (towards the construction of a clinical and biological model)]. Psihiatriya [Psychiatry]. 2021;19(1):6–15. (In Russ.) DOI: https://doi.org/10.30629/2618-6667-2021-19-1-6-15 4. Gallego JA, Blanco EA, Husain Krautter S, et al. Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis. Schizophr Res. 2018;202:64–71. DOI: https://doi.org/10.1016/j.schres.2018.07.019 5. Vasilieva AI, Govorin NV. [Neuromarkers and indicators of endothelial dysfunction in patients in the clinic of the first psychotic episode]. Zabajkal'skij medicinskij vestnik [The Transbaikalian medical bulletin]. 2011;(1):26–32. (In Russ.) 6. Monji A, Kato TA, Mizoguchi Y, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:115–21. DOI: https://doi.org/10.1016/j.pnpbp.2011.12.002 7. Kozlovskiy VL. [Endogenous factors of neurodestruction (the pharmacologic aspects)]. Farmakol Toksikol. 1990;53(5):7–13. (In Russ.) PMID: 2174797 8. Sakharov AV, Mynduskin IV, Tereshkov PP. [Indicators of neuro-repair in patients with the first episode of schizophrenia during antipsychotic therapy]. Sibirskij vestnik psihiatrii i narkologii [Siberian Herald of Psychiatry and Addiction Psychiatry]. 2020;4(109):15–20. (In Russ.) DOI: https://doi.org/10.26617/1810-3111-2020-3(108)-15-20 9. Burgoyne RD. Neuronal calcium sensor proteins: generating diversity in neuronal Ca2+ signalling. Nat Rev Neurosci. 2007;8(3):182–93. DOI: https://doi.org/10.1038/nrn2093 10. Semple BD, Kossmann T, Morganti-Kossmann MC. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab. 2010;30(3):459–73. DOI: https://doi.org/10.1038/jcbfm.2009.240 11. Jarnagin K, Grunberger D, Malkins M, et al. [Identification of monocyte chemotactic protein 1 surface residues that influence signaling through the CCR2 receptor]. Biohimiya [Biochemistry]. 1999;(38):16167–77. (In Russ.) DOI: https://doi.org/10.1021/bi9912239 12. Lin Y, Peng Y, Zhu C, et al. Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia. Shanghai Arch Psychiatry. 2017;29(5):287–94. DOI: https://doi.org/10.11919/j.issn.1002-0829.217093 13. Beumer W, Drexhage RC, De Wit H, et al. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37(12):1901–11. DOI: https://doi.org/10.1016/j.psyneuen.2012.04.001 14. Bhattacharjee S, Zhao Y, Dua P, et al. MicroRNA-34a-Mediated Down-Regulation of the Microglial-Enriched Triggering Receptor and Phagocytosis-Sensor TREM2 in Age-Related Macular Degeneration. PLoS One. 2016;11(3):e0150211. DOI: https://doi.org/10.1371/journal.pone.0150211 15. Lima Giacobbo B, Doorduin J, Klein HC, et al. Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Mol Neurobiol. 2019;56(5):3295–312. DOI: https://doi.org/10.1007/s12035-018-1283-6 16. Angelucci F, Brenè S, Mathé AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry. 2005;10(4):345–52. DOI: https://doi.org/10.1038/sj.mp.4001637 17. Amoli MM, Khatami F, Arzaghi SM, et al. Over-expression of TGF-β1 gene in medication free Schizophrenia. Psychoneuroendocrinology. 2019;99:265–70. DOI: https://doi.org/10.1016/j.psyneuen.2018.10.009 18. Verena T, Carsten T. VEGF – A Stimulus for Neuronal Development and Regeneration in the CNS and PNS. Curr Protein Pept Sci. 2018;19(6):589–97. DOI: https://doi.org/10.2174/1389203719666180104113937 19. Oliveira SL, Pillat MM, Cheffer A, et al. Functions of neurotrophins and growth factors in neurogenesis and brain repair. Cytometry A. 2013;83(1):76–89. DOI: https://doi.org/10.1002/cyto.a.22161 20. Galasko D, Bell J, Mancuso JY, et al. Alzheimer's Disease Cooperative Study. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology. 2014;82(17):1536–42. DOI: https://doi.org/10.1212/WNL.0000000000000364 21. Ganguli R, Yang Z, Shurin G, et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 1994;51(1):1–10. DOI: https://doi.org/10.1016/0165-1781(94)90042-6 22. Villa A, Vegeto E, Poletti A, Maggi A. Estrogens, neuroinflammation, and neurodegeneration. Endocr Rev. 2016;37(4):372–402. DOI: https://doi.org/10.1210/er.2016-1007 23. Khandaker GM, Cousins L, Deakin J, et al. Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3):258–70. DOI: https://doi.org/10.1016/S2215-0366(14)00122-9 24. Yakushenko EV, Lopatnikova YuA, Sennikov SV. [Interleukin-18 and its role in the immune response]. Medicinskaya immunologiya [Medical immunology]. 2005;7(4):355–64. (In Russ.) DOI: https://doi.org/10.15789/1563-0625-2005-4-355-364 25. Voronina EV, Lobanova NV, Yakhin IR, Romanova NA. [The role of tumor necrosis factor-alpha in the immunopathogenesis of diseases of various etiologies and its significance in the development of anticytokine therapy with monoclonal antibodies]. Medicinskaya immunologiya [Medical immunology]. 2018;20(6):797–806. (In Russ.) DOI: https://doi.org/10.15789/1563-0625-2018-6-797-806 26. Mesnyankina OA, Yanchevskaya EYu, Ben M. [Fractalkin: pathogenetic role and diagnostic possibilities]. Kubanskij nauchnyj medicinskij vestnik [Kuban Scientific Medical Bulletin]. 2017;1(2):148–51. (In Russ.) DOI: https://doi.org/10.25207/1608-6228-2017-2-148-151 27. Fan Q, He W, Gayen M, et al. Activated CX3CL1/Smad2 Signals Prevent Neuronal Loss and Alzheimer's Tau Pathology-Mediated Cognitive Dysfunction. J Neurosci. 2020;40(5):1133–44. DOI: https://doi.org/10.1523/JNEUROSCI.1333-19.2019

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM